DUBLIN, Aug. 06, 2015 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/3cwtc3/investigation) has announced the addition of the "Investigation Report on China's Budesonide Market, 2010-2019" report to their offering.
With the climatic and environmental changes, seasonal asthma has become the main reason for respiratory ailments. According to an epidemiological survey, the incidence of respiratory ailments is 16% of the incidence of all diseases. About 280 million people in the world suffer from different degrees of seasonal asthma, more so in industrialized countries and regions where tobacco consumption is high. 5% of adults and 20% of children there have been attacked by this disease and many of them come down with bronchial asthma induced by chronic cough.
Nearly 300 million people in China contract respiratory ailments, among of which over 50 million suffer from a cough with an annual growth rate of 4% and 15-20 million asthma.
Budesonide, an adrenocortical hormone, was developed by AstraZeneca in the 1990s. It is mainly used for the treatment of non-glucocorticoid dependent or glucocorticoid-dependent bronchial asthma and chronic obstructive pulmonary disease (COPD). In June 1997, budesonide aerosol got FDA's approval. In recent years, with the steady growth of the global demand, budesonide has occupied an important position in the TOP 10 respiratory drugs.
In 1994, China approved the import of budesonide for clinical purposes. After being marketed by Astra (Wuxi) in China in 1995, budesonide develops fast with annual sales rising from CNY 60 million in 2005 to CNY 595 million in 2014 and CAGR reaching up to 29% during the period of 2005-2014. Budesonide enjoys a vast demand in China. Currently, budesonide in the Chinese market mainly come from the following companies: Lunan Better Pharmaceutical Co., Ltd, Orion Corporation (Finland), WELLCOME AUSTRALIA LTD.(AU), SYNMOSA BIOPHARMA CORPORATION (TW) and Astra AB (Sweden). While they all take up certain shares in the market, WELLCOME AUSTRALIA LTD.(AU) has the largest market share of 88% with sales value reaching up to CNY 524 million in 2014.
Key Topics Covered:
1 Related Concepts of Budesonide
2 Market Profile of Budesonide in China
3 Survey on Sales Status of Budesonide in China, 2010-2014
4 Survey on Market Share of Major Manufacturers of Budesonide in China, 2010-2014
5 Survey on Dosage Forms of Budesonide in China, 2010-2014
6 Reference Price of Budesonide in Chinese Hospitals in 2014
7 Major Manufacturers of Budesonide in Chinese Market, 2010-2014
8 Market Outlook of Budesonide in China, 2015-2019
- Shanghai Sine Pharmaceutical Co Ltd
- Lunan Better Pharmaceutical Co., Ltd
- Astra AB (Sweden)
- Wellcome Australia Ltd
- Synmosa Biopharma Corporation
For more information visit http://www.researchandmarkets.com/research/3cwtc3/investigation
Media Contact: Laura Wood , +353-1-481-1716, firstname.lastname@example.org
SOURCE Research and Markets